Navigation Links
Transgenomic, Inc. Reports Second Quarter 2007 Results
Date:8/19/2007

ic variation and mutation analysis. Their offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of pharmacogenomics and personalized medicine. Specific offerings include WAVE(R) DHPLC Systems, related consumables and assay kits, cytogenetics automated systems, and Transgenomic Discovery and CLIA Lab Services. Transgenomic Discovery and Lab Services utilize their technology and expertise to provide a menu of mutation scanning tests for over 700 cancer-associated genes and more than 60 validated diagnostic tests to meet the needs of pharmaceutical and biotech companies, research and clinical laboratories, physicians and patients. For more information about the innovative systems, products and services offered by Transgenomic, please visit: http://www.transgenomic.com

Forward-Looking Statement

Certain statements in this press release constitute "forward-looking statements" of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's reports to the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, e
'/>"/>

SOURCE Transgenomic, Inc.

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... -- On January 20th, 2010, the inaugural European ... Professionals (ISMPP) will be held at the Royal ... 100 attendees are expected at this prestigious event, ... publishers, medical writers and medical agencies to discuss ... impact of guidelines and regulations such as GPP-2, ...
(Date:12/14/2009)... Calif., Dec. 14 Array BioPharma Inc. ... AMGN ) today announced that they entered into ... Array,s small-molecule glucokinase activator program, including ARRY-403, currently ... in patients with Type 2 diabetes. ... will receive an upfront payment of $60 million ...
(Date:12/14/2009)... third edition of Infusion Nursing: An ... the Infusion Nurses Society (INS), includes Totect(®), the ... are a group of chemotherapy medications including daunorubicin, ... in the treatment of various types of cancer ... to the INS publication: "In September 2007, the ...
(Date:12/14/2009)... Decision Resources, one of the world,s leading research ... finds that, owing to the launches of several ... increase more than sevenfold from $790 million in ... United States, France, Germany, Italy, Spain, the United ... entitled Atrial Fibrillation finds that a ...
Breaking Biology Technology:Announcing ISMPP EU 2010 - the First European Meeting of the International Society for Medical Publication Professionals, Royal College of Physicians, London, UK, January 20, 2010 2Array BioPharma and Amgen Partner in Type 2 Diabetes 2Array BioPharma and Amgen Partner in Type 2 Diabetes 3Array BioPharma and Amgen Partner in Type 2 Diabetes 4Array BioPharma and Amgen Partner in Type 2 Diabetes 5Array BioPharma and Amgen Partner in Type 2 Diabetes 6Array BioPharma and Amgen Partner in Type 2 Diabetes 7Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2
... T.J. Higley and Roy Eksteen, Tosoh Bioscience LLC, Montgomeryville, ... Introduction: , ... to ensure method , robustness. Factors ... are required to be consistent by GMP/GLP protocols. During a ...
... Authors: T.J. Higley, Tosoh Bioscience LLC, Tatsunari Yoshida, Tosoh , ... , The TSKgel Amide-80 column provides excellent selectivity for ... carbamoyl , functionalities bonded to a silica base material. , ... , The separation of peptides with many acidic ...
... Republic www.dataapex.com , e-mail: vins@dataapex.com ... Slovak Republic, , ... Determination of MW distribution of polymers ... is a simple, affordable solution for process quality control or ...
Other Biology Technology:Mobile Phase Optimization for the Analysis of an Antibody-Based Fusion Protein and Aggregates using a TSKgel Super SW3000 Size-Exclusion Column 2Mobile Phase Optimization for the Analysis of an Antibody-Based Fusion Protein and Aggregates using a TSKgel Super SW3000 Size-Exclusion Column 3Separation of Peptides by Hydrophilic Interaction Chromatography Using TSKgel Amide-80 2Separation of Peptides by Hydrophilic Interaction Chromatography Using TSKgel Amide-80 3Separation of Peptides by Hydrophilic Interaction Chromatography Using TSKgel Amide-80 4Practical Aspects of Evaluation of Chromatographic Data in Size Exclusion Chromatography 2Practical Aspects of Evaluation of Chromatographic Data in Size Exclusion Chromatography 3Practical Aspects of Evaluation of Chromatographic Data in Size Exclusion Chromatography 4Practical Aspects of Evaluation of Chromatographic Data in Size Exclusion Chromatography 5
(Date:12/14/2009)... an international team that has used DNA samples from ... of North America,s woolly mammoths and ancient horses. , ... Sciences professor Duane Froese and his colleagues counters an ... and teeth. That analysis concluded that more than half ... disappeared about 13,000 years ago. , In the ...
(Date:12/14/2009)... Society (BMES) have founded a new journal Cardiovascular ... CVET is a forum for research on all ... first issue of the new quarterly journal will appear ... at Springer, Annals of Biomedical Engineering and ... Engineering and Technology will present a wide spectrum ...
(Date:12/14/2009)... the United Nations Framework Convention on Climate Change ... hosted the ,Bend the Trend, event on Sunday ... and premiere the screening of the new ,Environmental ... Europe, a joint project of the European Environment ... ESA, is a series of short films showing ...
Breaking Biology News(10 mins):Biomedical Engineering Society's new journal to be published by Springer 2'Environmental Atlas of Europe' unveiled at COP15 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 14743 1DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 14743 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 14743 3OncoGenex Reports Third Quarter 2009 Financial Results 14740 1OncoGenex Reports Third Quarter 2009 Financial Results 14740 2OncoGenex Reports Third Quarter 2009 Financial Results 14740 3OncoGenex Reports Third Quarter 2009 Financial Results 14740 4OncoGenex Reports Third Quarter 2009 Financial Results 14740 5OncoGenex Reports Third Quarter 2009 Financial Results 14740 6OncoGenex Reports Third Quarter 2009 Financial Results 14740 7OncoGenex Reports Third Quarter 2009 Financial Results 14740 8Cepheid to Webcast Upcoming Financial Presentations 14737 1Cepheid to Webcast Upcoming Financial Presentations 14737 2
... As if creaking joints and hardening of the arteries weren't ... and the Christiana Care Health System in Newark has now ... , "When you are young, your veins are nice and ... College of Health Sciences, said. "But as you grow older, ...
... return severely failing hearts to their normal function, potentially ... research. , The mechanical devices, known as Left Ventricular ... very severe heart failure whilst they await transplantation. The ... Medicine, shows that using an LVAD combined with certain ...
... compete with large animal scavengers by producing repugnant chemicals ... -- such as decaying meat, seeds and fruit, a ... microbes as decomposers and pathogens in ecological communities. But ... compete with larger animals could be an important and ...
Other Biology News:Researchers show that veins stiffen as we age 2Researchers show that veins stiffen as we age 3Researchers show that veins stiffen as we age 4Mechanical 'artificial hearts' can remove need for heart transplant by returning heart to normal 2Microbes compete with animals for food by making it stink 2Microbes compete with animals for food by making it stink 3Microbes compete with animals for food by making it stink 4
... developed to significantly increase the shelf life ... is increased at room temperature storage conditions ... product is subjected to 0.2 micron filtration, ... This formulation insures consistently high levels of ...
... Blot Strong Antibody Stripping Solution is effective ... that have been developed with chemiluminescence or ... not recommended for stripping colorimetric substrates (TMB, ... possible to effectively remove substrates that precipitate ...
...
... system, 100-120 V, is used for biolistic ... system includes the Helios gene gun, helium ... syringe kit, tubing cutter, Helios gene gun ... dimensions of the gene gun are 20 ...
Biology Products: